BRPI0914457A2 - composto, composição farmacêutica, método para reduzir angiotensão convertendo atividade de enzima, método para tratar uma perturbação relacionada com o sistema de renina-angiotensina aldosterona, método para tratar derrame cerebral - Google Patents
composto, composição farmacêutica, método para reduzir angiotensão convertendo atividade de enzima, método para tratar uma perturbação relacionada com o sistema de renina-angiotensina aldosterona, método para tratar derrame cerebralInfo
- Publication number
- BRPI0914457A2 BRPI0914457A2 BRPI0914457A BRPI0914457A BRPI0914457A2 BR PI0914457 A2 BRPI0914457 A2 BR PI0914457A2 BR PI0914457 A BRPI0914457 A BR PI0914457A BR PI0914457 A BRPI0914457 A BR PI0914457A BR PI0914457 A2 BRPI0914457 A2 BR PI0914457A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- angiotension
- renin
- compound
- reducing
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000036454 renin-angiotensin system Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19641708P | 2008-10-17 | 2008-10-17 | |
| PCT/US2009/061037 WO2010045575A2 (en) | 2008-10-17 | 2009-10-16 | Compositions and methods for treatment of renin-angiotensin aldosterone system (raas)-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0914457A2 true BRPI0914457A2 (pt) | 2015-10-27 |
Family
ID=42107279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0914457A BRPI0914457A2 (pt) | 2008-10-17 | 2009-10-16 | composto, composição farmacêutica, método para reduzir angiotensão convertendo atividade de enzima, método para tratar uma perturbação relacionada com o sistema de renina-angiotensina aldosterona, método para tratar derrame cerebral |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110257130A1 (pt) |
| EP (1) | EP2358707A4 (pt) |
| JP (1) | JP2012505919A (pt) |
| KR (1) | KR20110097770A (pt) |
| CN (1) | CN102256970A (pt) |
| AU (1) | AU2009305619B2 (pt) |
| BR (1) | BRPI0914457A2 (pt) |
| CA (1) | CA2741060A1 (pt) |
| IL (1) | IL212381A0 (pt) |
| RU (1) | RU2011119533A (pt) |
| WO (1) | WO2010045575A2 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015195070A1 (en) * | 2014-06-19 | 2015-12-23 | Robert Shorr | Pharmaceutical compounds |
| CN104496971B (zh) * | 2014-12-26 | 2016-08-17 | 浙江永太科技股份有限公司 | 一种作为raas系统双重抑制剂的化合物 |
| CN104447899B (zh) * | 2014-12-26 | 2017-01-04 | 浙江永太科技股份有限公司 | 一种用于制备肾素-血管紧张素-醛固酮系统双重抑制剂的化合物的中间体 |
| CN104478992B (zh) * | 2014-12-26 | 2017-07-18 | 浙江永太药业有限公司 | 一种用于肾素‑血管紧张素‑醛固酮系统双重抑制剂的化合物的制备方法 |
| CN104496969B (zh) * | 2014-12-26 | 2016-08-17 | 浙江永太药业有限公司 | 一种用于肾素-血管紧张素-醛固酮系统双重抑制剂的化合物 |
| EP3429577B1 (en) * | 2016-03-14 | 2021-12-29 | NeoStrata Company, Inc. | N-lipoic -amino acid or peptide, derivatives and their uses |
| US12435056B2 (en) | 2016-03-14 | 2025-10-07 | Neostrata Company, Inc. | N-lipoic-amino acid or peptide, derivatives and their uses |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3243370A1 (de) * | 1982-11-24 | 1984-05-24 | Basf Ag, 6700 Ludwigshafen | Benzoylthioverbindungen, ihre herstellung und verwendung als arzneimittel |
| CA2459172C (en) * | 2001-08-08 | 2011-07-05 | Takeda Chemical Industries, Ltd. | Bicyclic compound, production and use thereof |
| KR100973451B1 (ko) * | 2002-09-13 | 2010-08-02 | 유겐가이샤 오가 리서치 | 멜라닌 소거제 |
| AU2003286389A1 (en) * | 2002-11-29 | 2004-06-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Ace-inhibitors having antioxidant and nitricoxid-donor activity |
| EP1844002A1 (en) * | 2005-02-02 | 2007-10-17 | Vitae Pharmaceuticals, Inc. | 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors |
| JP2008174453A (ja) * | 2005-04-28 | 2008-07-31 | Iwaki Kk | 頭皮脱毛治療剤 |
| EP2010488A2 (en) * | 2006-04-05 | 2009-01-07 | Vitae Pharmaceuticals, Inc. | Renin inhibitors |
| US20100144827A1 (en) * | 2006-12-20 | 2010-06-10 | Medwell Laboratories Ltd. C/O Ngt Technological Incubator | Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof |
| TW200838501A (en) * | 2007-02-02 | 2008-10-01 | Theravance Inc | Dual-acting antihypertensive agents |
| WO2010096677A2 (en) * | 2009-02-17 | 2010-08-26 | Invasc Therapeutics, Inc. | Dihydrolipoic acid derivatives comprising nitric oxide and therapeutic uses thereof |
-
2009
- 2009-10-16 RU RU2011119533/04A patent/RU2011119533A/ru not_active Application Discontinuation
- 2009-10-16 AU AU2009305619A patent/AU2009305619B2/en not_active Ceased
- 2009-10-16 CA CA2741060A patent/CA2741060A1/en not_active Abandoned
- 2009-10-16 WO PCT/US2009/061037 patent/WO2010045575A2/en not_active Ceased
- 2009-10-16 EP EP09821336A patent/EP2358707A4/en not_active Withdrawn
- 2009-10-16 BR BRPI0914457A patent/BRPI0914457A2/pt not_active IP Right Cessation
- 2009-10-16 CN CN2009801508776A patent/CN102256970A/zh active Pending
- 2009-10-16 JP JP2011532292A patent/JP2012505919A/ja active Pending
- 2009-10-16 KR KR1020117010670A patent/KR20110097770A/ko not_active Withdrawn
- 2009-10-16 US US13/124,601 patent/US20110257130A1/en not_active Abandoned
-
2011
- 2011-04-14 IL IL212381A patent/IL212381A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2741060A1 (en) | 2010-04-22 |
| EP2358707A2 (en) | 2011-08-24 |
| KR20110097770A (ko) | 2011-08-31 |
| WO2010045575A2 (en) | 2010-04-22 |
| AU2009305619B2 (en) | 2012-06-21 |
| EP2358707A4 (en) | 2012-08-22 |
| CN102256970A (zh) | 2011-11-23 |
| RU2011119533A (ru) | 2012-11-27 |
| JP2012505919A (ja) | 2012-03-08 |
| WO2010045575A3 (en) | 2010-07-08 |
| US20110257130A1 (en) | 2011-10-20 |
| IL212381A0 (en) | 2011-06-30 |
| AU2009305619A1 (en) | 2010-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0914457A2 (pt) | composto, composição farmacêutica, método para reduzir angiotensão convertendo atividade de enzima, método para tratar uma perturbação relacionada com o sistema de renina-angiotensina aldosterona, método para tratar derrame cerebral | |
| BRPI0915267A2 (pt) | Composto, composição farmacêutica livre de pirogênio, e, método de tratamento de uma doença ou uma condição | |
| BR112012004333A2 (pt) | composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio. | |
| BR112013009154A2 (pt) | sistema de acionamento hidráulico para acionar uma carga e método para operar um sistema de acionamento hidráulico | |
| BRPI0915382A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio. | |
| BRPI1011528A2 (pt) | controlador para sistema de acionamento de carga. | |
| BRPI0906141A2 (pt) | sistema de tratamento de pressão reduzida | |
| BR112012028530A2 (pt) | composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno | |
| FR2936475B1 (fr) | Procede de degradation de modes de freinage | |
| BRPI0912111A2 (pt) | composto, composição farmacêutica, método para tratar, controlar ou prevenir uma doença ou distúrbio, e, forma de dosagem unitária única | |
| DE602009000958D1 (de) | System zum Einrahmen von Kraftfahrzeugkarosserien oder Baugruppen davon | |
| BRPI0911077A2 (pt) | método para tratamento de biomassa | |
| EP2327488A4 (en) | SHEAR METHOD FOR PANEL | |
| BRPI0916947A2 (pt) | sistema de acionamento estereostático | |
| BRPI1009459A2 (pt) | método e sistema para controlar uma unidade de leito adsorvente. | |
| BRPI0822641A2 (pt) | Um método e um sistema para operação de uma máquina de trabalho | |
| BRPI0917372A2 (pt) | arruela, parafuso ou porca | |
| BRPI0823071A2 (pt) | metodo para operacao de um sistema de freio de uma maquina de trabalho e sistema de freio para uma maquina de trabalho | |
| EP2412748A4 (en) | PROCESS FOR REDUCING VOLATILE ORGANIC COMPOUNDS IN COMPOSITE RESIN PARTICLES AND COMPOSITE RESIN PARTICLES | |
| BRPI0923856A2 (pt) | composto, composição farmacêutica, uso de um composto, e método para tratar uma doença ou distúrbio. | |
| BR112012004137A2 (pt) | método para ligar uma composição de borracha a um substrato, e, composição | |
| DK2260130T3 (da) | Fremgangsmåde til øget enzymaktivitet | |
| BRPI0910620A2 (pt) | método de tratamento de plantas cítricas para redução de infecção bacteriana | |
| BRPI0916885A2 (pt) | composição farmacêutica, e, método para tratar uma infecção bacteriana | |
| EP2411623A4 (en) | ACTIVE SLUDGE VALVE SYSTEM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |